June 2025 in “British Journal of Dermatology” Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
June 2025 in “Neurology India” Anti-SRP myopathy can be linked to systemic lupus erythematosus and may improve with specific treatment.
June 2025 in “British Journal of Clinical Pharmacology” Chemotherapy often causes skin and hair issues, but early management can help improve patient care.
June 2025 in “Revista Foco” JAK inhibitors effectively treat severe alopecia areata with manageable side effects.
June 2025 in “Journal of Education Health and Sport” Oral JAK inhibitors show promise for treating alopecia areata but have challenges like relapse and side effects.
June 2025 in “Histopathology” Epithelial elements in superficial angiomyxomas are non-neoplastic growths mimicking embryogenesis.
June 2025 in “BMJ Case Reports” Axitinib treatment turned a man's grey hair back to black.
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
May 2025 in “JEADV Clinical Practice” Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
May 2025 in “International Journal of Dermatology” Alopecia areata patients are more likely to develop systemic lupus erythematosus.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
April 2025 in “Cellular and Molecular Biology” Human dermal stem/progenitor cells can divide and differentiate more than hair follicle dermal papilla cells.
April 2025 in “Vestnik dermatologii i venerologii” JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
April 2025 in “Turkish Journal of Hematology” Nilotinib may cause gray hair to return to its original color.
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
March 2025 in “Journal of Clinical Medicine” Iron chelators can effectively reduce hair loss and improve hair growth in autoimmune alopecia.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
March 2025 in “Journal of Education Health and Sport” Alopecia areata causes hair loss due to immune issues, and while new treatments show promise, no universally effective solution exists yet.
Janus kinase inhibitors are the most supported treatment for pediatric alopecia areata, while other options have limited evidence.
February 2025 in “PubMed” Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.
New therapies like JAK inhibitors, PRP, and stem cell treatments show promise for better alopecia management.
January 2025 in “Skin Health and Disease” Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.
January 2025 in “FASKES Jurnal Farmasi Kesehatan dan Sains” Erythrina subumbrans leaves may help treat hair loss.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.